The FDA’s expanded approval was supported by data from the Phase 2 CABOSUN trial (n=157) in patients with previously untreated RCC. In the study, treatment with cabozantinib led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with sunitinib. Moreover, treatment with cabozantinib was associated with a 52% reduction in the rate of disease progression or death (hazard ratio [HR] 0.48, 95% CI: 0.31-0.74; P=0.0008). The median PFS was higher in the cabozantinib group vs sunitinib group (8.6 months vs 5.3 months), which translated to a 3.3 month (62%) improvement.
Regarding safety, hypertension, diarrhea, hyponatremia, hypophosphatemia, palmar-plantar erythrodysesthesia (PPE), fatigue, increased ALT, decreased appetite, stomatitis, pain, hypotension, and syncope were the most frequent all-cause Grade 3-4 adverse reactions (at least 5%) in patients treated with cabozantinib.
Cabometyx, a kinase inhibitor, was initially approved in 2016 for the treatment of advanced RCC in patients who had previously received anti-angiogenic therapy. It is available as 20mg, 40mg, and 60mg strength tablets.
For more information call (650) 837-7000 or visit Cabometyx.com.